Uppdrag | 20 Jan 2025
Setterwalls has advised Sound Bioventures, Novo Holdings och Pueros Bioventures in connection with investment in AnaCardio
Setterwalls has advised Sound Bioventures, Novo Holdings and Pureos Bioventures in connection with a USD 19 million Series A extension financing round in AnaCardio.
The current investors Flerie, Industrifonden, and Fredrik and Ann-Helene Ljungström, also participated in the financing round.
AnaCardio is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure. The raised funds will be used to complete the phase 1b/2a GOAL-HF1 study, and to prepare and initiate start-up activities for the subsequent phase 2b study.
Contact:
Ola Grahn, Elsa Economou Olsson, Jonathan Lindström, Jonatan Blomqvist, Maria Bergström, Karolina Jivebäck Pap, Axel Mattsson
Practice areas:
